CMND vs. BPTH, HSTO, SLRX, NTBL, LSDI, CYCC, CNSP, QLGN, INM, and CMRA
Should you be buying Clearmind Medicine stock or one of its competitors? The main competitors of Clearmind Medicine include Bio-Path (BPTH), Histogen (HSTO), Salarius Pharmaceuticals (SLRX), Notable Labs (NTBL), Lucy Scientific Discovery (LSDI), Cyclacel Pharmaceuticals (CYCC), CNS Pharmaceuticals (CNSP), Qualigen Therapeutics (QLGN), InMed Pharmaceuticals (INM), and Comera Life Sciences (CMRA). These companies are all part of the "pharmaceutical preparations" industry.
Bio-Path (NASDAQ:BPTH) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, community ranking, dividends, risk, institutional ownership, profitability and valuation.
Bio-Path has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, Clearmind Medicine has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.
Bio-Path received 281 more outperform votes than Clearmind Medicine when rated by MarketBeat users.
5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 3.1% of Bio-Path shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Bio-Path currently has a consensus price target of $40.00, suggesting a potential upside of 1,392.54%. Given Clearmind Medicine's higher possible upside, analysts plainly believe Bio-Path is more favorable than Clearmind Medicine.
Bio-Path's return on equity of -265.38% beat Clearmind Medicine's return on equity.
In the previous week, Bio-Path had 1 more articles in the media than Clearmind Medicine. MarketBeat recorded 2 mentions for Bio-Path and 1 mentions for Clearmind Medicine. Bio-Path's average media sentiment score of 1.00 beat Clearmind Medicine's score of 0.33 indicating that Clearmind Medicine is being referred to more favorably in the news media.
Summary
Clearmind Medicine beats Bio-Path on 6 of the 11 factors compared between the two stocks.
Get Clearmind Medicine News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Clearmind Medicine Competitors List
Related Companies and Tools
